Conferences - Results from #1120

Viewing 1121-1140 of 11745 articles

ESMO 2023: Adjuvant Everolimus in Patients with Completely Resected Very High-Risk RCC and Clear Cell Histology: Results from the Phase III SWOG S0931 (EVEREST) Trial

ESMO 2023: Phase II Trial Evaluating the Efficacy of Pembrolizumab Combined with Vorinostat in Patients with Recurrent And/or Metastatic Squamous Cell Carcinoma of the Penis – Subgroup Analysis of the PEVOsq Basket Trial

ESMO 2023: Invited Discussant – PET-MUSE and the Phase 3 THOR Study

ESMO 2023: Invited Discussant: KEYNOTE-641, KEYNOTE-991, MAGNITUDE & ProBio

ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma

ESMO 2023: AVENANCE: Subgroup Analysis of Patients with Advanced Urothelial Carcinoma with Histological Variants from a Real-World Study of Avelumab First-Line

ESMO 2023: Invited Discussant: More Than Therapy Alone

ESMO 2023: Real World Effectiveness of Single Agent Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Based on Line of Therapy and Impact of Prior Platinum Chemotherapy and PD-1/PD-L1 Inhibitors

ESMO 2023: Erdafitinib vs Chemotherapy in Patients With Advanced or Metastatic Urothelial Cancer With Select FGFR Alterations: Subgroups From the Phase 3 THOR Study

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

ESMO 2023: Phase II Trial Compares Tobemstomig Alone or with Tiragolumab vs. Atezolizumab in Untreated Metastatic Urothelial Cancer

ESMO 2023: Biomarkers of Treatment - Related Toxicity in Advanced Urothelial Carcinoma Patients Treated with Enfortumab Vedotin: Analysis of UNITE Study

ESMO 2023: Staging of Muscle-Invasive Bladder Cancer: The Impact of PET Imaging [PET-MUSE]

ESMO 2023: A Pooled Meta-Analysis of Salvage Nivolumab/Ipilimumab after Nivolumab in Patients with Advanced Renal Cell Carcinoma

ESMO 2023: SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 vs Intravesical BCG in Patients with BCG-Naive High-Risk Non–Muscle-Invasive Bladder Cancer

ESMO 2023: Healthcare Data from the STAMPEDE Docetaxel and Zoledronic Acid Comparisons: Incidence of Fracture Related Hospitalisations in Men with De Novo High Risk and Metastatic Hormone Sensitive Prostate Cancer

ESMO 2023: MAGNITUDE Three-Year Update and Final Analysis: Niraparib with Abiraterone Acetate plus Prednisone as First-Line Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alteration

ESMO 2023: Effects of Enzalutamide on Overall Survival +/- Early Docetaxel in Participants Aged Less than 70 Yrs vs Greater than or Equal to 70 Yrs in ENZAMET (ANZUP 1304)

ESMO 2023: EMBARK: Health-Related Quality of Life in nmHSPC Patients with High-Risk BCR

ESMO 2023: External Validation of a Digital Pathology-Based Multimodal Artificial Intelligence (MMAI)-Derived Model in High-Risk M0/M1 Prostate Cancer Starting ADT in the Docetaxel or Abiraterone Phase 3 STAMPEDE Trials

52
53
54
55
56
57
58
59
60
61